Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06303505 · ClinicalTrials.gov registry record · Phase 1
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
A Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by Tubulis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 15
- Study locations
NCT06303505 is a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer that is actively recruiting participants, run by Tubulis. The registered enrollment target is 250 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The trial reports 15 study locations across 7 states.
The verdict
NCT06303505, a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Tubulis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients receive increasing doses of TUB-040 until the maximal tolerated dose is found. In dose optimization, at least two doses are compared with each other to determine which dose is optimal for patients. TUB-040 is given IV every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Conditions Studied
Interventions
- DRUG TUB-040
Study Locations (15)
Other
- UZ Leuven - Leuven
- Charité Universitätsmedizin Berlin - Berlin
- University Hospital Cologne Department of Internal Medicine I - Cologne
- Arensia Exploratory Medicine - Cluj-Napoca
- Clínica universidad de Navarra - Madrid
- NEXT Oncology Madrid - Madrid
- Arensia Exploratory Medicine - Kyiv
- Guy's Hospital - London
Ohio
- Christ Hospital - Cincinnati
- Ohio State University - Columbus
Alabama
- The University of Alabama - Birmingham
New York
- Mount Sinai - New York
Oklahoma
- OU Health Stephenson Cancer Center - Oklahoma City
Texas
- Next Oncology Dallas - Irving
Virginia
- Next Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-06-12 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06303505
The ClinicalTrials.gov registry entry for NCT06303505 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Tubulis, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which TUB-040 is the first listed.
NCT06303505 reports 15 study locations spanning 7 distinct geographic areas - top geographies include Other, Ohio, Alabama.
Frequently Asked Questions
What is clinical trial NCT06303505 about?
NCT06303505 is a clinical study titled "FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC". The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate w...
What is the current status of trial NCT06303505?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-06-12. Estimated completion is 2027-12.
What conditions does trial NCT06303505 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer.
What interventions are being tested in trial NCT06303505?
The interventions under investigation include: TUB-040 (DRUG).
Who is sponsoring clinical trial NCT06303505?
This trial is sponsored by Tubulis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06303505 being conducted?
This trial has 15 study locations across Alabama, New York, Ohio, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.